Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 403 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carcinoma In Situ Clear all
Recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

NCT04712851
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Terminated No phase listed Observational

A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients

NCT00519272
View directory record Official record
Conditions
Cervical Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
Procedure · Other · Genetic + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Phase 1 Interventional

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

NCT01009437
View directory record Official record
Conditions
Breast Cancer
Interventions
ritonavir, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 23, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT07322263
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Active, not recruiting No phase listed Observational

MRI Characterization of Mammographically Detected DCIS

NCT03495011
View directory record Official record
Conditions
Breast Cancer, Stage 0
Interventions
Breast MRI, Laboratory Biomarker Analysis
Diagnostic Test · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
122 participants
Timeline
2018 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer

NCT00110136
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
St. John's Wort
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

NCT04022772
View directory record Official record
Conditions
Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Best Practice, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 23, 2026, 2:22 AM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

NCT02908178
View directory record Official record
Conditions
Ductal Carcinoma In Situ
Interventions
Sentinel lymph node biopsy (SLNB)
Procedure
Lead sponsor
Yale University
Other
Eligibility
67 Years to 94 Years · Female only
Enrollment
28,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 23, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional Results available

Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

NCT03766009
View directory record Official record
Conditions
Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Usual Care, Web-based decision aid
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
56
States / cities
Dublin, California • Emeryville, California • Martinez, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Letrozole in Preventing Breast Cancer in Postmenopausal Women

NCT00090857
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
35 Years to 120 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 23, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

NCT03546972
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity, Overweight, Premalignant Lesion
Interventions
Behavioral, Psychological or Informational Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Phase 4 Interventional

Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer

NCT00742222
View directory record Official record
Conditions
Breast Cancer, Carcinoma, Lumpectomy, Ductal Carcinoma in Situ
Interventions
Electronic Brachytherapy, Intracavitary accelerated partial breast irradiation
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
8
States / cities
Tuscaloosa, Alabama • Montebello, California • Orange Park, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy

NCT03061175
View directory record Official record
Conditions
Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Internet-Based Intervention, Survey Administration
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Charlestown, Massachusetts • New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

NCT06159842
View directory record Official record
Conditions
Facial Cutaneous Squamous Cell Carcinoma in Situ
Interventions
Aminolevulinic Acid 20% Topical Solution with Blue Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 23, 2026, 2:22 AM EDT
Completed No phase listed Observational Results available

Impact of Radiation Therapy on Breast Conservation in DCIS

NCT02248662
View directory record Official record
Conditions
DCIS
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Hanover, New Hampshire • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC

NCT00321048
View directory record Official record
Conditions
Breast Neoplasms, Carcinoma, Ductal, Adenocarcinoma
Interventions
Active Breathing Coordinator
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 23, 2026, 2:22 AM EDT
Active, not recruiting Phase 3 Interventional

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874
View directory record Official record
Conditions
Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Procedure · Other · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
895
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Erlotinib Prevention of Oral Cancer (EPOC)

NCT00402779
View directory record Official record
Conditions
Oral Cancer
Interventions
Erlotinib, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 23, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Breast MRI as a Preoperative Tool for DCIS

NCT00605982
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma in Situ
Interventions
MRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 59 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 23, 2026, 2:22 AM EDT
Not yet recruiting Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

NCT07725796
View directory record Official record
Conditions
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
UGN-501
Biological
Lead sponsor
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Completed No phase listed Observational

Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast

NCT00665782
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Psychosocial Effects of Cancer and Its Treatment
Interventions
laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, psychosocial assessment and care, therapeutic conventional surgery
Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 23, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

NCT05951179
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
44
States / cities
Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 2:22 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

NCT03735290
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
ilixadencel, Pembrolizumab
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 23, 2026, 2:22 AM EDT